Difference between revisions of "Part:BBa K1645998:Experience"
(→Applications of BBa_K1645998) |
(→Applications of BBa_K1645998) |
||
| Line 4: | Line 4: | ||
how you used this part and how it worked out. | how you used this part and how it worked out. | ||
| − | ===Applications of BBa_K1645998=== | + | [[File:BBa_K1645998-Experience.png]]===Applications of BBa_K1645998=== |
This part can be used along with Cas9 once it is placed in front of an appropriate promoter in order to suppress transcription of a gene that is under lacI promoter. | This part can be used along with Cas9 once it is placed in front of an appropriate promoter in order to suppress transcription of a gene that is under lacI promoter. | ||
Our experiment was conducted in BL21. The characterization data using this part from our experiments demonstrates that when using this sgRNA co-transformed with dCas9, the RFP intensity which uses the LacI promoter is being suppressed by 41% compared with our control RFP not containing cas9 system. Here is the Flow Cytometry results, where the grey is control and blue is this biobrick used with dCas9. Significant repression of RFP can be seen in this graph. | Our experiment was conducted in BL21. The characterization data using this part from our experiments demonstrates that when using this sgRNA co-transformed with dCas9, the RFP intensity which uses the LacI promoter is being suppressed by 41% compared with our control RFP not containing cas9 system. Here is the Flow Cytometry results, where the grey is control and blue is this biobrick used with dCas9. Significant repression of RFP can be seen in this graph. | ||
Revision as of 12:53, 26 September 2015
This experience page is provided so that any user may enter their experience using this part.
Please enter
how you used this part and how it worked out.
===Applications of BBa_K1645998===
This part can be used along with Cas9 once it is placed in front of an appropriate promoter in order to suppress transcription of a gene that is under lacI promoter.
Our experiment was conducted in BL21. The characterization data using this part from our experiments demonstrates that when using this sgRNA co-transformed with dCas9, the RFP intensity which uses the LacI promoter is being suppressed by 41% compared with our control RFP not containing cas9 system. Here is the Flow Cytometry results, where the grey is control and blue is this biobrick used with dCas9. Significant repression of RFP can be seen in this graph.
User Reviews
UNIQ1a8f39be9a707328-partinfo-00000000-QINU UNIQ1a8f39be9a707328-partinfo-00000001-QINU